Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.695 USD | +0.53% | +25.75% | -23.93% |
May. 13 | JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating | MT |
May. 10 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.93% | 770M | |
+7.83% | 111B | |
+11.27% | 106B | |
-12.26% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.92% | 16.81B | |
+38.47% | 12.54B | |
-24.52% | 8.09B |
- Stock Market
- Equities
- PRME Stock
- News Prime Medicine, Inc.
- Transcript : Prime Medicine, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-16-2023 01